GlassScriptPhysician profile
Eric Munchrath
NPI 1235592890
$19,473.43
in general payments reported to CMS, 2019-2025
44 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,129 · 2022: $5,509 · 2023: $7,022 · 2024: $2,822 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,938 · Food and Beverage: $5,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,937.50 |
| Food and Beverage | $5,898.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,460.73 | 2021-2025 | |
| Eko Health, INC. | $4,999.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $670.41 | 2021-2025 | Arexvy, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $638.95 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.49 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $510.29 | 2024-2025 | General - Vascular Intervention, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Novo Nordisk INC | $493.59 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $412.13 | 2023-2025 | Freestyle Libre 3, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Inspire Medical Systems, INC. | $355.13 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $311.26 | 2021-2022 | |
| Amgen INC. | $252.43 | 2021-2025 | Repatha, Otezla |
| Genzyme Corporation | $227.91 | 2024 | |
| Pfizer INC. | $215.10 | 2022-2025 | |
| Edwards Lifesciences Corporation | $177.30 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $142.30 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Munchrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.